Gradalis Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Gradalis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014103
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals, is a biopharmaceutical company which focuses on the development and commercialization of therapies for the treatment of cancer. Its developmental pipeline comprises of candidates for various cancer indications which include ovarian, breast, melanoma, Ewing’s sarcoma, non-small cell lung, colon, hepatocellular, carcinoid, and sarcomas. Gradalis developed a proprietary immunotherapy platform, Vigil which is utilized in various advanced cancer indications. Vigil is intended to stimulate and enhance the patient’s natural mechanism for recognizing and killing the cancer cells. The company operates a manufacturing facility located in Carrolton, Texas. Gradalis is headquartered in Dallas, Texas, the US.

Gradalis Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gradalis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Gradalis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gradalis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Gradalis Raises US$24 Million In Series B Financing 10
Partnerships 11
Gradalis Enters into Agreement with Genentech 11
Gradalis Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 12
Gradalis Enters Into Co-Development Agreement With Baylor College of Medicine 13
Gradalis Inc – Key Competitors 14
Gradalis Inc – Key Employees 15
Gradalis Inc – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
May 04, 2016: Gradalis Appoints Sunil Joshi Chief Executive Officer 17
Product News 18
10/24/2016: Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board 18
10/17/2016: Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX 19
01/03/2017: Cryoport Supports Gradalis’ Vigil Platform in Clinical Trials for Autologous Immunotherapies for Multiple Cancers 20
Clinical Trials 21
Aug 29, 2016: Gradalis Announces Dosing of First Patient in Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast Cancer 21
Apr 26, 2016: Gradalis, Announces Initiation of a Phase 2 Study using Gradalis’ Vigil Immunotherapy in Combination with Anti-PD-1 Technology to Treat Patients with Advanced Non-Small Cell Lung Cancer 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Gradalis Inc, Pharmaceuticals & Healthcare, Key Facts 2
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gradalis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gradalis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gradalis Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Gradalis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gradalis Raises US$24 Million In Series B Financing 10
Gradalis Enters into Agreement with Genentech 11
Gradalis Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 12
Gradalis Enters Into Co-Development Agreement With Baylor College of Medicine 13
Gradalis Inc, Key Competitors 14
Gradalis Inc, Key Employees 15
Gradalis Inc, Other Locations 16

★海外企業調査レポート[Gradalis Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oxford Biodynamics Plc-医療機器分野:企業M&A・提携分析
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a biotechnology company that discovers and develops biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, …
  • Alberici Corp:企業の戦略的SWOT分析
    Alberici Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • KeyCorp (KEY):電力:M&Aディール及び事業提携情報
    Summary KeyCorp (KeyCorp) is a bank holding company that offers a range of retail and commercial banking, consumer finance, commercial mortgage and special servicing, commercial leasing, investment management, and investment banking products and services through its principle subsidiary, KeyBank Nat …
  • Eversource Energy:企業の発電所・SWOT分析2018
    Eversource Energy - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • XsunX Inc (XSNX):企業の財務・戦略的SWOT分析
    XsunX Inc (XSNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • IntriCon Corp (IIN):企業の財務・戦略的SWOT分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products comprise glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support product …
  • Adimab LLC-製薬・医療分野:企業M&A・提携分析
    Summary Adimab LLC (Adimab) is an antibody discovery technology provider that offers antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic dis …
  • BioLight Israeli Life Sciences Ltd (BOLT):医療機器:M&Aディール及び事業提携情報
    Summary BioLight Israeli Life Sciences Ltd (Bio-Light), formerly Bio Light Israeli Life Sciences Investments Ltd is an ophthalmic company that discovers, develops and commercializes products and product candidates for various ophthalmic conditions. The company invests in managing and commercializing …
  • Implants International Ltd:企業の製品パイプライン分析
    Summary Implants International Ltd (Implants International) is a medical device company that manufactures, designs, and develops orthopedic implants, bio-engineering, and other products for the healthcare sector. The company’s products include revision systems, hip stems, hip stem ancillaries, aceta …
  • Waagner-Biro Aktiengesellschaft:企業の戦略・SWOT・財務情報
    Waagner-Biro Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report Summary Waagner-Biro Aktiengesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • The British United Provident Association Limited:企業の戦略・SWOT・財務分析
    The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report Summary The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Union Investment Group:企業の戦略・SWOT・財務情報
    Union Investment Group - Strategy, SWOT and Corporate Finance Report Summary Union Investment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SPR Therapeutics LLC:製品パイプライン分析
    Summary SPR Therapeutics LLC (SPR Therapeutics) is a medical device company that develops and commercializes neurostimulation based therapies and medical devices. The company develops and commercializes therapies for post-surgical pain, neuropathic pain, and musculoskeletal pain. It also provides pe …
  • United Internet AG:企業のM&A・事業提携・投資動向
    United Internet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's United Internet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • National Bank of Canada:企業の戦略・SWOT・財務分析
    National Bank of Canada - Strategy, SWOT and Corporate Finance Report Summary National Bank of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Koninklijke Philips NV (PHIA):企業の製品パイプライン分析
    Summary Koninklijke Philips NV (Philips) is a diversified technology company that develops and manufactures medical systems and consumer electronics products. The company offers products and solutions in the areas of diagnostic imaging, enterprise diagnostic informatics, image-guided therapy, ultras …
  • China Agri-Industries Holdings Ltd (606):企業の財務・戦略的SWOT分析
    China Agri-Industries Holdings Ltd (606) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Eni SpA (ENI):企業の財務・戦略的SWOT分析
    Eni SpA (ENI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆